Study identification

PURI

https://redirect.ema.europa.eu/resource/36693

EU PAS number

EUPAS36692

Study ID

36693

Official title and acronym

First-line anticancer drugs in patients with advanced, primary Non-Small Cell Lung Cancer: drug-utilization and effectiveness studies from Tuscany Region healthcare database

DARWIN EU® study

No

Study countries

Italy

Study description

The aim of the project is evaluate drug utilization and the effectiveness of first-line anticancer therapies approved for the treatment of advanced, non-resectable, NSCLC patients between 2009 and 2019 in the Tuscany population. Two studies will be thus performed on a cohort of patients with not-resectable, primary NSCLC: a drugs utilization study and a survival study. For the purpose of this study two different, already pseudo-anonymized, data sources will be used: pathology registry and administrative healthcare data of the Tuscany region.

Study status

Finalised
Research institution and networks

Institutions

University of Siena, Department of Life Sciences and Departement of Medicine, Surgery and Neuroscience Siena, Via Aldo Moro 2

Contact details

Spini Andrea

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Data collection

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Other

More details on funding

No external funding
Study protocol
Initial protocol
English (2.18 MB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable